Navigation Links
Dendreon Reports First Quarter 2009 Financial Results
Date:5/6/2009

erapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercializatio
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
2. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
3. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
4. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
5. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
10. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
11. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Follow us on ... nanomaterial with diameter ranging between 2 to 10 ... nanophotonics materials market. The unique electroluminescent, photoluminescent, photo-physical, ... quantum confinement effect render the nanoparticles versatile and ... scientific, technological, and commercial applications. A host of ...
(Date:5/6/2015)... 2015   University of Maryland (UM) Ventures ... signing of an exclusive option by Biomecite Diagnostics for ... develop diagnostics to detect inflammatory bowel diseases (IBD), such ... Florian Fricke and James White ... University of Maryland School of Medicine,s Institute for Genome ...
(Date:5/6/2015)... TAMPA, Fla. , May 6, 2015  Oxis ... International, Inc. OTC: OXIS, OXI.PA, announced today that ... Oncology, Division of Cancer Medicine at the University of ... board.  Dr. Yee is also Professor, Department of Immunology, ... Therapy, Center for Cancer Immunology Research at the University ...
(Date:5/6/2015)... Whitefox ( http://www.whitefox.com ... has signed an agreement with  California ... the delivery of an industrial scale membrane system. The ... water, energy and emissions in the production ... project is fully aligned with ...
Breaking Biology Technology:Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 2Expanding Applications & Full-Scale Commercialization to Drive the Global Quantum Dots Market, According to a New Report by Global Industry Analysts, Inc. 3Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3Whitefox Signs Agreement With Pacific Ethanol Inc. 2
... today announced successful,completion of the single-day oral dosing ... cancer patients with its new anti-cancer drug AXL1717,an,insulin-like ... effects,on the closely related insulin receptor. The study ... disease. The results showed that a single-day,dosing of ...
... objectively measure cardiopulmonary gas exchange in heart failure patients. It ... Abraham Kocheril, Professor of Medicine and Director of Clinical Electrophysiology ... ... Minneapolis-St. Paul, MN (PRWEB) May 6, 2009 ...
... CAMBRIDGE, Mass. May 5, 2009 Researchers at ... in collaboration with researchers from Worcester Polytechnic Institute (WPI), ... energy of impurities in semiconductor nanowires is affected by ... choice of the nanowire embedding medium. , The finding, ...
Cached Biology Technology:Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 2University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 3University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System 4Scientists demonstrate effect of confining dielectrics on semiconductor nanowire conductivity 2
(Date:4/2/2015)... 2015 Fingerprint Cards (FPC) has ... from the distributor World Peace Industrial Group (WPI), part ... although the major part of the shipments will take ... by smartphone manufacturers in China . ... the communicated revenue guidance of + 1 000 MSEK for ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/26/2015)... 2015 The Granite Club, ... athletic club, today announced it has implemented a state-of-the-art ... movement for members and staff, while restricting access to ... we selected FST,s IMID Access system because it has ... members and staff, in addition to unparalleled security," said ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... Nearly 90 percent of children and adults with a ... no evidence of cancer after receiving a novel, personalized ... pilot studies of bioengineered T cells that attack leukemia, ... 28 days after treatment. In all, 27 patients received ...
... international project has developed a free and open public ... and contentious world of gene patenting. In a ... published in this week,s Nature Biotechnology journal, ... keep up with the rapid explosion in information and ...
... Sophisticated recent experiments with ultrashort laser pulses support the ... algae, and some bacteria efficiently gather light to fuel ... mechanisms remain obscure, and the exact role that quantum ... than was once thought, according to an Overview Article ...
Cached Biology News:T cell immunotherapy: Promising results in children and adults with leukemia 2T cell immunotherapy: Promising results in children and adults with leukemia 3Who's patenting whose genome? 2Who's patenting whose genome? 3Quantum effects help cells capture light, but the details are obscure 2
... The InnoCyte Laminin-Based 96-well Cell Invasion ... capacity of cells using laminin as a ... potential anti-metastatic agents in vitro in a ... pore size is appropriate for all types ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... tumor, Polyclonal Antibody, Unconjugated ... at a dilution of 1/100. IP: ... WB: Use at an assay dependent ... Not tested in other applications. ...
... The Arabidopsis 2 Oligo Microarray Kit (V2), ... growth stages, and stress response. Each microarray contains ... of The Institute for Genomic Research (TIGR) and ... contains 5 standard 1 x 3? glass ...
Biology Products: